Daily pharma news is mostly second-hand aggregation. This post is the output of a pipeline that skips the aggregators and reads only first-hand sources: regulator databases, trial registries and company wire releases.
TL;DR — A small Python pipeline pulled 11 items from SEC EDGAR, openFDA, ClinicalTrials.gov and two wire feeds for Oct 4–October 5, 2026: 3 deal events, 0 FDA approvals and 12 Phase 2/3 readouts due within 90 days. Everything below is extracted heuristically — regex and keyword rules, no LLM — and every row links back to the original filing or press release.
Today’s Deals
| Company | Type | Upfront | Total (incl. milestones) | Source |
|---|---|---|---|---|
| Sensible Bio | financing | undisclosed | $47M | filing / release |
| — | collaboration | $355M | $1.20B | filing / release |
| Jasper Therapeutics, Inc. | license | undisclosed | undisclosed | filing / release |
Table 1: Deal events in the collection window, sorted by disclosed total value.
Deal-comp context: across 2 deals with disclosed values in the window, the median total is $624M; the largest is $47M (Sensible Bio). Milestone-heavy structures dominate, so headline totals overstate near-term cash.
Figure 1: Disclosed total deal values collected this window.
FDA & Approvals
No new approvals surfaced in openFDA for this window.
Readout Calendar
Table 3: Phase 2/3 studies on ClinicalTrials.gov with primary completion dates in the next 90 days (major sponsors prioritized, ranked by enrollment).
Sources
- Sensible Bio secures $47M Series A for mRNA therapy manufacturing platform
- CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug
- Jasper Therapeutics, Inc. 8-K mentioning license agreement
- A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
- Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD)
- CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
- A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprum
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast
- A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
- Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social
- Evaluation of a Disability-Focused Sexual and Reproductive Health Curriculum for Health St
- Evaluation of the Efficacy of an inTerdialytic “Ethanol 40% v/v - enoxapaRin 1000 U/mL” Lo
- Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFE
- A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
All items above are drawn from first-hand public sources — SEC filings, trial registries, and company releases. The same source-first discipline is what I apply to LLM agents in regulated programming.